

S1 Table. Patient characteristics in the full analytic sample. The unrestricted analysis was performed on the 944,127 patients with at least one SARS-CoV-2 laboratory, stratified by patients who did and did not receive disulfiram in the study period. Notation for number of patients: N (%); IQR = Interquartile range.

Patient Characteristics	Full Analytic Sample	Never Treated with Disulfiram	Treated with Disulfiram
All patients	944,127	941,894 (99.8)	2,233 (0.2)
Age (median [IQR])	64 [51, 72]	64 [51, 72]	51 [39, 61]
Gender (%)			
Male	834,982 (88.4)	832,936 (88.4)	2,046 (91.6)
Female	109,144 (11.6)	108,957 (11.6)	187 (8.4)
Race/Ethnicity (%)			
Non-Hispanic White	573,612 (60.8)	571,928 (60.7)	1,684 (75.4)
Non-Hispanic Black	204,379 (21.6)	204,130 (21.7)	249 (11.2)
Hispanic	80,154 (8.5)	80,025 (8.5)	129 (5.8)
Other or Unknown	85,982 (9.1)	85,811 (9.1)	171 (7.7)
Region (%)			
Continental	154,710 (16.4)	154,449 (16.4)	261 (11.7)
Midwest	197,872 (21.0)	197,216 (20.9)	656 (29.4)
North Atlantic	213,784 (22.6)	213,214 (22.6)	570 (25.5)
Pacific	178,755 (18.9)	178,310 (18.9)	445 (19.9)
Southeast	199,004 (21.1)	198,703 (21.1)	301 (13.5)
Charlson Score (%)			
0	361,778 (38.3)	360,708 (38.3)	1,070 (47.9)
1-2	373,407 (39.6)	372,503 (39.5)	904 (40.5)
3-4	132,843 (14.1)	132,657 (14.1)	186 (8.3)
>=5	50,689 (5.4)	50,644 (5.4)	45 (2.0)
Unknown	25,410 (2.7)	25,382 (2.7)	28 (1.3)
History of AUD (%)	100,873 (10.7)	98,910 (10.5)	1,963 (87.9)
Positive Covid-19 test (%)	167,327 (17.7)	167,139 (17.7)	188 (8.4)
Received ≥1 Covid-19 Vaccine Dose (%)	147,889 (15.7)	147,637 (15.7)	252 (11.6)

S2 Table. Patient characteristics in the restricted analysis. The restriction is to the 100873 patients who have a diagnosis of AUD, stratified by patients who did and did not receive disulfiram in the study period. Notation for number of patients: N (%); IQR = Interquartile range.

Patient Characteristics	Full Analytic Sample	Never Treated with Disulfiram	Treated with Disulfiram
All patients	100,873	98,910	1,963
Age (median [IQR])	60 [47, 68]	60 [48, 68]	51 [39, 60]
Gender (%)			
Male	93,631 (92.8)	91,813 (92.8)	1,818 (92.6)
Female	7,242 (7.2)	7,097 (7.2)	145 (7.4)
Race/Ethnicity (%)			
Non-Hispanic White	56,366 (55.9)	54,888 (55.5)	1,478 (75.3)
Non-Hispanic Black	28,022 (27.8)	27,804 (28.1)	218 (11.1)
Hispanic	8,897 (8.8)	8,782 (8.9)	115 (5.9)
Other or Unknown	7,588 (7.5)	7,436 (7.5)	152 (7.7)
Region (%)			
Continental	16,142 (16.0)	15,921 (16.1)	221 (11.3)
Midwest	21,896 (21.7)	21,322 (21.6)	574 (29.2)
North Atlantic	23,630 (23.4)	23,129 (23.4)	501 (25.5)
Pacific	18,034 (17.9)	17,637 (17.8)	397 (20.2)
Southeast	21,171 (21.0)	20,901 (21.1)	270 (13.8)
Charlson Score (%)			
0	38,724 (38.4)	37,799 (38.2)	925 (47.1)
1-2	40,641 (40.3)	39,816 (40.3)	825 (42.0)
3-4	15,002 (14.9)	14,831 (15.0)	171 (8.7)
>=5	6,413 (6.4)	6,372 (6.4)	41 (2.1)
Unknown	93 (0.1)	92 (0.1)	1 (0.1)
Positive Covid-19 test (%)	13,189 (13.1)	13,025 (13.2)	164 (8.4)
Received ≥1 Covid-19 Vaccine Dose (%)	12,737 (12.6)	12,518 (12.7)	219 (11.4)

The raw data cannot be shared publicly because of the policy of the VA Boston Healthcare System. Data are available from the VA Corporate Data Warehouse for researchers who meet the criteria for access to confidential data. Researchers should contact Danielle Valley (vog.av@yellav.elleinad).